Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Stock Based Compensation

Last Annual Value

29.27M

3-Year CAGR

65%

5-Year CAGR

137%

10-Year CAGR

%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Stock Based Compensation

PRME · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
29.27M
28.1%75.7%N/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
25.34M
-6.3%105.0%N/A
37.11M
9.7%9.5%33.3%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
8.48M
73.6%N/AN/A
27.87M
32.2%30.2%27.5%
35.04M
7.6%24.3%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
7.12M
-0.7%12.4%6.6%
0.00
N/AN/AN/A
28.01M
N/A57.5%N/A
49.07M
N/A-10.1%N/A
15.01M
99.2%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14